GenVec, Inc. is on the Cruelty Free Investing use of animals list because they conduct Pre-clinical studies of their drugs on animals to assess a product’s safety profile.
The company announced in the following press release that they conduct pre-clinical trials of their drugs on animals.
“GenVec’s HSV vaccine candidate generated effective immune responses in animal models; and is composed of two novel antigens, as well as a proprietary, non-human adenoviral vector. ” Read the full document.
GenVec, Inc. is a clinical-stage gene delivery company, which engages in the development of therapeutics and vaccines. The firm designs, tests, and manufactures adenoviral-based product candidates using its proprietary AdenoVerse platform. Its products include CGF166-Hearing Loss; GV2311-RSV Vaccine; and GV2207-HSV-2 Immunotherapeutic. The company was founded in December 1992 and is headquartered in Gaithersburg, MD. [Source: MarketWatch]
Company Website: http://www.genvec.com